Scholar Rock Holding Corporation received FDA approval for its drug ISEMBYLD (apitegromab) to treat spinal muscular atrophy (SMA) in patients aged 2 years and older. This approval opens a market opportunity exceeding $2 billion, with potential growth into younger patients, subcutaneous versions, and new diseases like facioscapulohumeral muscular dystrophy (FSHD). The company plans to resubmit its marketing authorization application in Europe and file for approval in Japan by the end of 2026, supported by a validated manufacturing facility. Scholar Rock currently holds $492.1 million in cash to fund operations through the second half of 2027 but may raise additional capital as commercialization progresses. Pricing and reimbursement remain key risks to watch.
Scholar Rock's recent FDA approval for its SMA drug is the subject, with Pluang's health sector data providing market context. As of Sep 16, 2026 02:01 WIB, among 91 priced US health-sector stocks on Pluang, 24 advanced while 66 declined. Notable movers include BBIO at USD 68.51 with a -5.35% change, NBIX at USD 149.47 down 4.93%, and FLNA at USD 0.69 falling 4.66%.
Evolution Petroleum reported a fiscal Q4 adjusted loss of $0.02 per share, missing the $0.01 estimate, but revenue rose 15% to $24.21 million, beating expectations. GAAP net income was $4.61 million, up from $3.41 million a year earlier, helped by un...
Veea Inc. shares surged 149.34% following the announcement of a potential business combination with NovaGen Group B.V. The deal aims to create NovaGen Health Networks, merging Veea's AI edge-computing tech with NovaGen's regenerative medicine. GeoNov...
Shares of Future FinTech Group (FTFT) dropped 28.61% after reversing previous gains, following a recent reverse stock split. Swarmer (SWMR) declined 28.36% as its post-IPO lock-up period expired, increasing potential share supply. Enova International...
Tigress Financial upgraded Intel's price target from $118 to $145, maintaining a "Buy" rating due to strong performance in Intel's Data Center and AI division, which saw a 59% revenue increase to $6.3 billion in Q2. The upcoming IPO of Altera, where ...
Uber Technologies reported a 25% year-over-year increase in gross bookings to $53.7 billion in Q1 2026, driven by growth in ride-hailing, delivery, grocery, retail, and membership services. CEO Dara Khosrowshahi's recent purchase of 141,000 shares wo...
